`Argentum Pharm. LLC v. Alcon Research, Ltd.
`Case IPR2017-01053
`
`
`
`4.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`5.
`
`No court or administrative body has ever denied my application for
`
`admission to practice before it.
`
`6.
`
`No court or administrative body has ever imposed sanctions or
`
`contempt citations on me.
`
`7.
`
`I have read and will comply with the Office Patent Trial Practice
`
`guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`8.
`
`I understand that I will be subject to the USPTO Code of Professional
`
`Responsibility set forth in 37 CPR. §§ 11.101 et seq. and will be subject to
`
`disciplinary jurisdiction under 37 CPR. § 11.19(a).
`
`9.
`
`I have not applied to appear pro hac vice in any other proceedings
`
`before the Office in the last three (3) years.
`
`10.
`
`I am familiar with the subject matter at issue in the present
`
`proceeding.
`
`I represented Alcon in litigation in the U.S. District Court for the
`
`District of Delaware in which the same patent was at issue: Alcon Research, Ltd.
`
`v. Mylan Pharmaceuticals Inc. & Mylan Inc, No. 1:13-cv-Ol332 (SLR); Alcon
`
`Research, Ltd. v. Wockhardt Ltd, Wockhardt Bio AG, & Wockhardt USA, LLC,
`
`No. 1:13—CV-02040 (SLR); and Alcon Research, Ltd. v. Watson Laboratories, Inc.
`
`
`
`et al., No. l:l4-cv-00647 (SLR). In addition, I worked with the fact and expert
`
`witnesses in those district court cases.
`
`11.
`
`I hereby declare that all statements made herein of my own
`
`knowledge are true and that all statements made on information and belief are
`
`believed to be true, and further that these statements were made with the
`
`knowledge that willful false statements and the like so made are punishable by fine
`
`or imprisonment, or both, under 18 U.S.C. § 1001.
`
`
`{/x
`
`lexander S/!an
`
`